Capricor Therapeutics (CAPR) Tops Q3 EPS by 1c

Capricor Therapeutics (NASDAQ: CAPR) reported Q3 EPS of ($0.26), $0.01 better than the analyst estimate of ($0.27). Revenue for the quarter came in at $1.59 million versus the consensus estimate of $420 thousand.

For earnings history and earnings-related data on Capricor Therapeutics (CAPR) click here.

You May Also Be Interested In

• onsemi downgraded by TD Cowen after Synaptics deal clouds growth story
• Darden Restaurants (DRI) PT Raised to $240 at UBS as Stock Remains a 'Quality Compounder'
• Freedom Broker Starts Copart (CPRT) at Buy